These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 9042215

  • 21. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
    Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A.
    Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
    [Abstract] [Full Text] [Related]

  • 22. Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters.
    Qiu T, Yang Q, Li XR, Yang H, Qiu LL, Wang L.
    Cancer Invest; 2007 Feb; 25(7):563-8. PubMed ID: 17952741
    [Abstract] [Full Text] [Related]

  • 23. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S, Chapman W, McLaughlin J, Andrulis IL.
    Cancer J; 2000 Feb; 6(5):302-8. PubMed ID: 11079169
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R, Daidone MG, Veneroni S, Benini E, Scarfone G, Zanaboni F, Villa A, Presti M, Danese S, Bolis G.
    Cancer; 1998 Jan 01; 82(1):159-67. PubMed ID: 9428493
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM, Tang R, Chen JR, Wu MC, Chien HT, Changchien CR, Hsieh LL.
    Oncol Rep; 2004 Nov 01; 12(5):1045-51. PubMed ID: 15492791
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
    Qiu LL, Hua PY, Ye LL, Wang YC, Qiu T, Bao HZ, Wang L.
    Cancer Detect Prev; 2007 Nov 01; 31(1):45-9. PubMed ID: 17292563
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Clinical importance of serum anti-p53 antibodies as tumor markers].
    Sakai H, Okamoto E.
    Rinsho Byori; 2002 Oct 01; 50(10):970-5. PubMed ID: 12451677
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    Murray PV, Soussi T, O'Brien ME, Smith IE, Brossault S, Norton A, Ashley S, Tavassoli M.
    Br J Cancer; 2000 Dec 01; 83(11):1418-24. PubMed ID: 11076647
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.